Asthma
Conditions
Brief summary
The purpose of this study is to compare Symbicort Single Inhaler treatment with the Best Conventional Practice in patients with persistent asthma
Interventions
Sponsors
AstraZeneca
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
12 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Diagnosis of asthma \< 3 months * Prescribed daily use of glucocorticosteroids for at least 3 months prior to Visit 1
Exclusion criteria
* Smoking history \> 10 pack-years * Asthma exacerbation requiring change in asthma treatment during the last 14 days prior to inclusion * Any significant disease or disorder that my jeopardize the safety of the patient. Additional inclusion and
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Time to first severe asthma exacerbation | — |
Secondary
| Measure | Time frame |
|---|---|
| Mean use of as-needed medication | — |
| Prescribed asthma medication | — |
| Patient reported Outcomes | — |
| Number of asthma exacerbations | — |
| Safety: Adverse Events, Serious Adverse Events and discontinuations due to Adverse Events | — |
| Induced sputum will be sampled from a subset of patients | — |
| All variables assessed over the 6 months treatment period | — |
| Health care resource use | — |
Countries
Canada
Outcome results
None listed